DOUBLEIP
DoubleIP provides mobile marketing, mobile applications and services, internet applications, proximity marketing, bulk SMS and many more.
DOUBLEIP
Industry:
B2B Computer Marketing SMS Software
Founded:
2009-01-01
Address:
Athens, Attiki, Greece
Country:
Greece
Website Url:
http://www.doubleip.com
Total Employee:
11+
Status:
Active
Contact:
+30 210 6180155
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Font Awesome Domain Not Resolving Mobile Non Scaleable Content Nginx
Similar Organizations
i-DOCS
i-DOCS develops products and offers services designed for Financial Institutions, Telecom Operators, Utility, Insurance, Courier.
Persistence AI
Persistence AI provides sales assistants that engage and qualify existing leads and automatically turn them into high-intent inbound calls.
Zoznam Mobile
Zoznam Mobile offers services in the implementation of web applications and provides content, technical and marketing support using SMS.
Official Site Inspections
http://www.doubleip.com
- Host name: redirection.dnsmadeeasy.com
- IP address: 96.45.83.90
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "DoubleIP"
Double Bond Pharmaceutical - Crunchbase Company Profile
Contact Email info@doublebp.com Phone Number +4673-5700203 Double Bond Pharmaceutical company which develops and commercialises innovative first-in-class approaches for …See details»
Q3 2024 - Double Bond Pharmaceutical
Nov 14, 2024 Full Company Name: Double Bond Pharmaceutical International AB (publ) Corporate identity: 556991-6082. Stock short name: DBP BSee details»
Double Bond Pharmaceutical International AB - Drug pipelines, …
Explore Double Bond Pharmaceutical International AB with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, Disease Domain:Neoplasms ...See details»
Double Bond Pharmaceutical International AB | LinkedIn
Double Bond Pharmaceutical International AB | 1 289 följare på LinkedIn. Double Bond Pharmaceutical is a fast growing pharmaceutical company that develops and commercializes …See details»
DoubleIP - Crunchbase Company Profile & Funding
DoubleIP provides mobile marketing, mobile applications and services, internet applications, proximity marketing, bulk SMS and many more.See details»
Double Bond Pharmaceutical International AB (publ)
Year Month Board Management Operational Management Overall; Market Cap (EUR) NOTES: † - Upcoming company / Assignment in upcoming company ♘ - Unicorn company Δ - Growth …See details»
Patent protecting Temodex and SI053 covering the Eurasian …
Patent protecting Temodex and SI053 covering the Eurasian market has been granted MON, OCT 29, 2018 08:11 CET The institution of Physical and Chemical Problems´ (Minsk) patent …See details»
Double Bond Pharmaceutical - Contacts, Employees, Board …
Double Bond Pharmaceutical company which develops and commercialises innovative first-in-class approaches for treatment of cancers.See details»
Double Bond Pharmaceutical International AB: DBP International …
Jun 12, 2020 The meeting granted discharge to the Board members and the CEO for the past year. directors: The following persons were re-elected as ordinary members: Per Stalhandske …See details»
Double Bond Pharmaceutical International AB (Double Bond …
了解Double Bond Pharmaceutical International AB (Double Bond Pharmaceutical International AB)公司的药物管线,治疗领域,技术平台,以及它的1项临床试,疾病领域:肿瘤,神经系统 …See details»
Supplement to Press Release: DBP International AB and Vivo …
Sep 19, 2023 The press release is supplemented with the paragraph "Further details of the agreements" Double Bond Pharmaceutical International AB (publ) (“DBP”) and Vivo …See details»
DBP International AB: Joint Venture agreement with Shijiazhuang …
May 21, 2020 E-mail: info@doublebp.com. Follow us on LinkedIn and Twitter! _____ Information on Double Bond Pharmaceutical International AB. DBP is a pharmaceutical company with the …See details»
Double Bond Pharmaceutical manufactures first GMP batch of SI053
Double Bond Pharmaceutical manufactures first GMP batch of SI053 WED, AUG 15, 2018 08:07 CET Double Bond Pharmaceuticals contract manufacturer of SI053 reports that they have …See details»
DBP International AB and Vivo Biopharma LLC Enter into Asset …
Sep 17, 2023 Double Bond Pharmaceutical International AB (publ) (“DBP”) and Vivo Biopharma LLC (“Vivo”), a wholly owned subsidiary of Sauvie Inc. (“Sauvie”) today announced that they …See details»
Q3 rapport 2021 - Double Bond Pharmaceutical
Full Company Name: Double Bond Pharmaceutical International AB (publ) Corporate identity: 556991-6082. Stock short name: DBP BSee details»
DBP International: The Investigator’s Brochure for the SI-053 phase …
May 14, 2021 More about Temodex/SI-053: Temodex, which is a locally acting formulation of temozolomide developed by RI PCP in Minsk, Belarus, is registered for marketing as the first …See details»
Double Bond Pharmaceutical receives Eurasian patent for the …
Oct 23, 2019 Double Bond Pharmaceuticals patent application for organ-specific administration of hydrophilic cancer drug to the liver which forms the basis for the BeloGal® technology …See details»
Zoono : DBP International AB, Zoono's products will be available at ...
Oct 29, 2020 After replenishing its stock, Double Bond Pharmaceuticals subsidiary Drugsson AB has now received an order from Apotek365. The products will soon be sold at online …See details»
Pneumonia – Double Bond Pharmaceutical
[fusion_builder_column type="1_6" layout="1_6" spacing="" center_content="no" hover_type="none" link="" min_height="" hide_on_mobile="small-visibility,medium ...See details»
DBP International: The clinical protocol for the SI-053 phase I trial ...
May 12, 2021 Preparation of the trial protocol was accomplished in close collaboration with Investigators as well as contract research organization, CATO SMS. "The completion of the …See details»